Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pilarquim (shanghai) co ltd - glyphosate present as the isopropylamine salt - soluble concentrate - glyphosate present as the isopropylamine salt glycine active 450.0 g/l - herbicide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pilarquim (shanghai) co ltd - 2,4-d present as the dimethylamine and diethanolamine sa - soluble concentrate - 2,4-d present as the dimethylamine and diethanolamine sa - phenoxy acids-2,4-d - active - 625.0 - g/l - herbicide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pilarquim(shanghai) co., ltd - lambda-cyhalothrin - capsule suspension - lambda-cyhalothrin pyrethroid active 250.0 g/l - insecticide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pilarquim(shanghai) co., ltd - chlorothalonil - suspension concentrate - chlorothalonil benzene active 720.0 g/l - fungicide

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

alpha-cypermethrin 10% w/w ec

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

glyphosate ipa w/w sl 41%

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - vemurafenib 240mg (as a co-precipitate with hypromellose acetate succinate (800 mg total));  ;   - film coated tablet - 240 mg - active: vemurafenib 240mg (as a co-precipitate with hypromellose acetate succinate (800 mg total))     excipient: colloidal silicon dioxide croscarmellose sodium hyprolose iron oxide red macrogol 3350 magnesium stearate polyvinyl alcohol purified talc titanium dioxide - indicated for the treatment of unresectable stage iiic or stage iv metastatic melanoma positive for the braf v600 mutation.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - vemurafenib - film coated tablets - vemurafenib 240 mg - vemurafenib - vemurafenib - zelboraf is indicated for the treatment of brafv600 mutation-positive unresectable or metastatic melanoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - trametinib dimethyl sulfoxide 0.5635mg equivalent to trametinib 0.5 mg;   - film coated tablet - 0.5 mg - active: trametinib dimethyl sulfoxide 0.5635mg equivalent to trametinib 0.5 mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose magnesium stearate mannitol microcrystalline cellulose opadry yellow 03b120006 purified water sodium laurilsulfate - mekinist in combination with dabrafenib is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma. mekinist as a monotherapy is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is an intolerance to braf inhibitors or braf inhibitors cannot be used. mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - trametinib dimethyl sulfoxide 2.254mg equivalent to trametinib 2 mg;   - film coated tablet - 2 mg - active: trametinib dimethyl sulfoxide 2.254mg equivalent to trametinib 2 mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose magnesium stearate mannitol microcrystalline cellulose opadry pink ys-1-14762-a purified water sodium laurilsulfate - mekinist in combination with dabrafenib is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma. mekinist as a monotherapy is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is an intolerance to braf inhibitors or braf inhibitors cannot be used. mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy.